MANE
What one share of Veradermics holds
Pharmaceutical Preparations
We are a dermatologist-founded, late clinical-stage biopharmaceutical company, or the “Company,” “we,” “us,” or “our”, focused on developing innovative therapeutics to address pervasive treatment challenges in highly prevalent aesthetic and dermatological conditions.
Veradermics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$6.44 |
|---|---|
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$4.84 |
| Cash and investments | $7.64 |
| Book value | $19.47 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2024 | — | −$37.05 | $0.00 | −$32.14 | — | −$65.79 |
| 2025 | — | −$111.91 | $0.03 | −$96.14 | — | −$161.40 |